EP3704108
IRAK4 hemill í samsetningu með BCL-2 hemli til notkunar við meðferð á krabbameini
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
30.10.2018EP published:
24.4.2024EP application number:
18873778.7
EP translation filed:
3.6.2024Grant published:
15.7.2024EPO information:
European Patent Register
Max expiry date:
29.10.2038Expiry date:
29.10.2026Next due date:
31.10.2026
Title in English:
IRAK4 INHIBITOR IN COMBINATION WITH A BCL-2 INHIBITOR FOR USE IN TREATING CANCERLanguage of the patent:
English
Timeline
Today
30.10.2018EP application
24.4.2024EP Publication
3.6.2024Translation submitted
15.7.2024Registration published
29.10.2026Expires
Owner
Name:
Curis, Inc.Address:
Ledgemont Research Center-Building C-500 Level 128 Spring Street, Lexington, MA 02421, US
Inventor
Name:
BOOHER, RobertAddress:
Davis, CA 95616, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762579502 PDate:
31.10.2017Country:
US
Classification
Categories:
A61K 31/635, A61K 31/5377, A61P 35/02
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 8.10.2024
Expires: 29.10.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 16.10.2025
Expires: 29.10.2026
Payer: Árnason Faktor ehf.